Stereotactic Radiotherapy for Adrenal Metastases: A Multi-Institutional Review of Patient Characteristics and Outcomes - Turkish Society for Radiation Oncology SBRT Group Study (Trod SBRT 10-004).

Autor: Elmali A; Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Akkus Yildirim B; Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey., Cengiz M; Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Yuce Sari S; Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Onal HC; Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey., Berber T; Department of Radiation Oncology, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey., Arslantas Erken A; Department of Radiation Oncology, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey., Zoto Mustafayev T; Department of Radiation Oncology, Acibadem Maslak Hospital, Istanbul, Turkey., Atalar B; Department of Radiation Oncology, Acibadem Maslak Hospital, Istanbul, Turkey., Unal I; Department of Radiation Oncology, Guven Hospital, Ankara, Turkey., Kaydihan N; Department of Radiation Oncology, Memorial Bahcelievler Hospital, Istanbul, Turkey., Oner Dincbas F; Department of Radiation Oncology, Memorial Bahcelievler Hospital, Istanbul, Turkey.; Department of Radiation Oncology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Oncology research and treatment [Oncol Res Treat] 2022; Vol. 45 (12), pp. 717-727. Date of Electronic Publication: 2022 Sep 16.
DOI: 10.1159/000527052
Abstrakt: Introduction: This study aimed to report the outcomes of stereotactic body radiotherapy (SBRT) for adrenal metastasis in a retrospective multi-institutional cohort.
Methods: The outcomes of 124 patients with 146 adrenal metastases who underwent SBRT within 11 years (2008-2019) were retrospectively evaluated. Survival outcomes were analyzed by the Kaplan-Meier method. Patient, tumor, and treatment characteristics and their effects on survival, local control (LC), and toxicity outcomes were analyzed by log-rank and multivariate Cox regression methods.
Results: The median age was 60 years. The most frequent primary tumor site was the lung, followed by the gastrointestinal system and breast. The adrenal gland was the only metastatic site in 49 (40%) patients. Median biologically effective dose (BED)10 was 61 Gy. The overall LC rate was 83%, and it was positively correlated with the BED10 and fraction dose. The 1- and 2-year local recurrence-free survival, overall survival (OS), and progression-free survival (PFS) rate was 79% and 69%, 83% and 60%, and 31% and 12%, respectively. OS significantly improved with non-lung cancer and <4-cm lesion and PFS with a fraction dose ≥8 Gy, BED10 >65 Gy, and an isolated adrenal metastasis. Fourteen patients reported an acute toxicity, and late toxicity was observed in 3 patients, including one grade 5.
Conclusion: A satisfactory LC rate was achieved for adrenal metastasis via SBRT. A higher BED10 and fraction dose were positive prognostic factors for tumor control. However, the main problem is DM in these patients, and systemic treatment options are needed to be improved.
(© 2022 S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje